MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Search

Guardant Health Inc

Fechado

SetorSaúde

93.86 2.95

Visão Geral

Variação de preço das ações

24h

Atual

Mín

93.14

Máximo

93.98

Indicadores-chave

By Trading Economics

Rendimento

-36M

-128M

Vendas

16M

281M

EPS

-0.5

Margem de lucro

-45.684

Funcionários

2,490

EBITDA

-37M

-119M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+41.45% upside

Dividendos

By Dow Jones

Próximos Ganhos

29 de abr. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-2.3B

11B

Abertura anterior

90.91

Fecho anterior

93.86

Sentimento de Notícias

By Acuity

50%

50%

154 / 349 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Guardant Health Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de abr. de 2026, 04:27 UTC

Notícias Principais

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

3 de abr. de 2026, 18:30 UTC

Notícias Principais

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3 de abr. de 2026, 18:14 UTC

Conversa de Mercado

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3 de abr. de 2026, 17:50 UTC

Conversa de Mercado

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3 de abr. de 2026, 17:44 UTC

Aquisições, Fusões, Aquisições de Empresas

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3 de abr. de 2026, 16:50 UTC

Notícias Principais

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3 de abr. de 2026, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

3 de abr. de 2026, 16:12 UTC

Ganhos

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3 de abr. de 2026, 15:56 UTC

Conversa de Mercado
Notícias Principais

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3 de abr. de 2026, 15:56 UTC

Conversa de Mercado
Notícias Principais

Global Equities Roundup: Market Talk

3 de abr. de 2026, 15:56 UTC

Conversa de Mercado
Notícias Principais

Global Forex and Fixed Income Roundup: Market Talk

3 de abr. de 2026, 15:20 UTC

Notícias Principais

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3 de abr. de 2026, 15:08 UTC

Aquisições, Fusões, Aquisições de Empresas

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3 de abr. de 2026, 14:11 UTC

Conversa de Mercado
Notícias Principais

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3 de abr. de 2026, 12:56 UTC

Conversa de Mercado

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3 de abr. de 2026, 08:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

3 de abr. de 2026, 08:01 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

3 de abr. de 2026, 08:01 UTC

Conversa de Mercado

Meituan's Profitability Likely to Improve This Year -- Market Talk

3 de abr. de 2026, 07:45 UTC

Conversa de Mercado

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3 de abr. de 2026, 06:17 UTC

Conversa de Mercado

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3 de abr. de 2026, 06:17 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

3 de abr. de 2026, 04:33 UTC

Conversa de Mercado

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3 de abr. de 2026, 04:33 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

3 de abr. de 2026, 04:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

3 de abr. de 2026, 04:01 UTC

Conversa de Mercado

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3 de abr. de 2026, 02:01 UTC

Conversa de Mercado

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3 de abr. de 2026, 01:59 UTC

Conversa de Mercado

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3 de abr. de 2026, 01:44 UTC

Conversa de Mercado

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3 de abr. de 2026, 01:22 UTC

Conversa de Mercado

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Comparação entre Pares

Variação de preço

Guardant Health Inc Previsão

Preço-alvo

By TipRanks

41.45% parte superior

Previsão para 12 meses

Média 132.72 USD  41.45%

Máximo 175 USD

Mínimo 110 USD

Com base em 20 analistas de Wall Street que oferecem metas de preço de 12 meses para Guardant Health Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

20 ratings

19

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

38.86 / 47.41Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

154 / 349 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat